MedTrace Logo

Effects of VR Training on Balance and Fall Risk of Patients With COPD

NCT06604754 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-17

No results posted yet for this study

Summary

The aim of this study is to determine whether Virtual Reality (VR) training has significant effects on balance and fall risk of patients with COPD, with a focus on the patient group (GOLD STANDARD I \& II). Additionally, the study determines whether VR training is a reliable substitute for traditional physical therapy balance.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

OTHER

Assigned Intervention for VR Training

In VR training patients use VR headsets to engage in virtual environments for 8 weeks where they perform exercises designed to enhance balance, coordination, and strength. Simultaneously, the VR platform incorporate pulmonary exercises that focus on improving breathing techniques, lung capacity, and overall respiratory health. Patients will engage in 3 sessions per week with total time duration of 45 to 60 minutes. VR-based training provides real-time feedback and adapts to the patient's progress, offering a comprehensive approach to rehabilitation that addresses both balance and pulmonary function in a motivating and controlled manner.

OTHER

Assigned Intervention for Traditional Physical Therapy Training

In Traditional physical therapy balance training for patients with chronic obstructive pulmonary disease (COPD) involves exercises designed to improve stability, strength, and coordination for duration of 8 weeks. These exercises, such as static balance tasks, dynamic movement drills, and strength training, help address the balance deficits often seen in COPD patients due to muscle weakness and reduced physical activity. Additionally, pulmonary effects are managed through breathing exercises such as deep breathing and pursed lip breathing that enhance respiratory functions, improve lung capacity and efficiency.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Suman Sheraz, PhD · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-12
Primary Completion
2025-11-30
Completion
2025-12-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06604754 on ClinicalTrials.gov